Respicardia receives Best Innovation of 2014 award from CRT and CV Pipeline for remedē System
Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the Best Innovation of 2014 from Cardiovascular Research Technologies (CRT) and CV Pipeline for the remedÄ"® System, the first and only implantable device for the treatment of central sleep apnea.
"Central sleep apnea (CSA) is associated with increased mortality and hospitalization and can affect nearly half of all heart failure patients and one-third of atrial fibrillation patients," stated Dr. Robin Germany, Chief Medical Officer of Respicardia. Kris James, a developer of the remedÄ" System, further notes that "the System is a fully implantable transvenous neurostimulation technology designed to stabilize CO2 levels and restore normal sleep and breathing to patients with CSA."
0 comments:
Post a Comment